MDM2 and lymphoma: To avoid the drawbacks of cytostatic effect induced by most of conventional targeted therapies, we decided to screen for apoptosis inducers using p53-mutant lymphoma cells among analogs of MMRi3, a primary hit of MDM2-MDM4 E3 ligase inhibitors (29) and identified MMRi36.